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SUMMARY 
The potential use of many promising novel drugs is limited by their inability to 
specifically reach their site of action after intravenous administration, without 
secondary effects to healthy tissues. In order to remediate to this problem, the 
protein transferrin has been extensively studied as a targeting molecule for the 
transport of drug and gene delivery systems to the brain and cancer cells. A wide 
range of delivery approaches have been developed to target the transferrin receptor 
and have already improved the specific delivery of transferrin-bearing therapeutic 
agents to their site of action.  
This review provides a summary of the numerous delivery strategies used to target 
the transferrin receptor and focuses on the recent therapeutic advances being made 
so far. 
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INTRODUCTION 
Recent advances in the fields of pharmacology and chemistry have led to the 
discovery of numerous potential drugs with promising therapeutic effects on various 
pathologies. However, the clinical use of these drugs following intravenous 
administration is currently limited by the lack of specific delivery to the pathological 
site, resulting in toxicity and secondary effects to healthy tissues. In order to 
remediate to this problem and enhance the therapeutic index of the drugs, it is crucial 
to target these drug candidates to their site of action.  
For more than twenty years, the protein transferrin (Tf) has been extensively studied 
as a targeting moiety for drug and gene delivery systems, since it is non-toxic, non-
immunogenic and biodegradable [1]. Transferrin receptors (TfR) are highly 
expressed on the brain capillary endothelium which forms the blood-brain barrier 
(BBB) in conjugation with other cellular components such as pericytes and 
astrocytes, in vivo [2]. As intravenously administered Tf was shown to reach the brain 
by receptor-mediated transcytosis across the BBB [3,4], TfR-targeting strategy 
quickly became the object of intense investigation for the brain delivery of central 
nervous system drug candidates: 100% of large-molecule drugs and more than 98% 
of small molecules drugs are otherwise prevented from penetrating the brain by the 
BBB [5]. In addition, TfR are present in abundance on the surface of cancer cells [6- 
9], thus allowing a specific uptake of TfR-targeted therapeutic drugs and genes by 
cancer cells overexpressing transferrin receptors. 
This review has for objective to present in a succinct form the numerous TfR-
targeting strategies developed so far in laboratory settings, while focusing on recent 
promising breakthroughs in this research area.   
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1. Transferrin and transferrin receptors: generalities 
1.1. Transferrin: structure and function 
Transferrin is part of a family of ubiquitous iron-binding glycoproteins including 
ovotransferrin, lactoferrin and melanotransferrin, whose primary function is the 
binding and transport of iron [10,11]. It is a monomeric glycoprotein containing about 
700 amino acids, with a large molecular mass (approximately 80 kDa). The 
polypeptide chain is folded into 2 structurally similar globular domains, known as the 
N- and C- lobes, and connected by a short linear peptide linker [11]. Each lobe 
contains one binding site for Fe3+ with a very high affinity (1022 M-1 at pH 7.4) [12]. 
The iron-free transferrin (apotransferrin) can therefore bind up to 2 Fe3+ ions to form 
ferro-transferrin (also called holotransferrin). The conformational changes of the 
protein occurring during iron binding have been shown to play a key role in the 
selective recognition by TfR. Consequently, diferric Tf has a 10 to 100-times higher 
affinity for the TfR than that of apoTf at physiological pH [13] and is therefore 
preferred as a TfR ligand in targeting studies.  
 
The principal biological function of Tf is to bind and distribute iron in the body.  Tf is 
the main iron-transporting protein in the body. It binds circulating iron taken from the 
diet and transports it into the systemic circulation to various target tissues. This 
transport is extremely important, as iron is required for various biological processes 
such as DNA synthesis, oxygen transport and electron transfer [11].  
Due to its iron binding mechanism, Tf also protects the cells against the toxic effects 
that could be generated by the presence of free iron in the circulation.  It is only up to 
30-40% iron-saturated under physiological conditions [14].  
In addition to its key role of iron transporter, Tf has been shown to bind other cations 
such as copper, gallium, zinc, manganese and aluminium ions [10]. 
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1.2. Transferrin receptor 
Cellular uptake of iron-loaded transferrin occurs through receptor-mediated 
endocytosis. The Tf receptor, referred to as TfR1 or CD71 in literature, is a type II 
transmembrane glycoprotein involved in iron uptake and cell growth regulation [15]. It 
consists of 2 identical monomers with an approximate molecular mass of 90 kDa 
each, linked by 2 disulfide bonds [1].  Each monomer is made of 3 distinct regions: a 
short N-terminal cytoplasmic domain, a hydrophobic transmembrane domain and a 
large, globular, extracellular C-terminal domain which contains the binding site for Tf 
[1,16]. As each monomer may bind a molecule of Tf, up to 2 molecules of Tf may 
bind one TfR and up to 4 Fe3+ ions within one Tf-TfR complex can be taken up by the 
cell. The recycling rate of TfR1 is very short (about 10-20 s) and can occur hundred 
times for each single receptor [53], making this receptor particularly efficient for the 
delivery of iron and therapeutics to cells.   
Another member of the Tf receptor family, referred to as TfR2, has been discovered. 
Although its extracellular domain shows 66% similarity with TfR1, TfR2 has a much 
lower affinity for Tf than TfR1 (25-fold lower) [17]. In addition, its expression is not 
correlated to LURQ OHYHOV LQWKHFHOOV ,WVĮ-transcript product is mostly expressed on 
KHSDWRF\WHVZKLOH LWVȕ-transcript is present on a wide range of tissues but at very 
low levels [17]. TfR2 would therefore be a less efficient target for transferrin-mediated 
drug and gene delivery to the brain or cancer cells.  
TfR1 is expressed at low levels in most human tissues, but is highly expressed on 
the vascular endothelium of brain capillaries [2]. It is also expressed at levels up to 
100-fold higher than those on normal cells on highly proliferative cells such as cancer 
cells [6-9].  Its increased expression on tumors is generally correlated with cancer 
progression and tumor stage [6-9].   
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This high expression of TfR on brain capillaries and cancer cells, together with the 
ability of the receptor to internalize with its ligand, makes this receptor a highly 
promising target for the delivery of therapeutics to the brain and cancer cells.  
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2. Transferrin receptor-mediated delivery of therapeutic agents to the brain 
Most therapeutic molecules, including small molecule drugs, proteins, peptides and 
genes, cannot reach the brain after intravenous administration due to their inability to 
cross the BBB [4,5]. As a result, various drugs with promising therapeutic effects in 
vitro are found to be ineffective for the treatment of neurological diseases such as 
3DUNLQVRQ¶VDQG$O]KHLPHU¶VGLVHDVHVas well as brain neoplasms.  
Widely expressed on the BBB, TfR has been widely investigated for the delivery of 
drugs and genes to the brain. The strategy employed here would be to use Tf or 
antibodies directed against TfR as TfR-targeting moieties. Therapeutic agents 
entrapped in TfR-targeted delivery systems would then be able to cross the BBB and 
to be delivered into the brain.  
 
2.2. Targeted drug delivery 
Many drugs are unable to cross the blood-brain barrier. In order to overcome this 
problem, therapeutic molecules have been encapsulated in delivery systems able to 
recognize TfR and to deliver their cargo to the brain. A wide range of delivery 
strategies, including the linkage of drugs to Tf/ anti-TfR antibody, complexation with 
TfR-targeted quantum rods, entrapment of the drugs in TfR-targeted liposomes, lipid 
nanocapsules, nanoparticles and micelles, have been investigated for TfR-mediated 
delivery of drugs to the brain (Figure 1).   
 
2.2.1. Linkage of drugs to Tf/ anti-TfR antibody 
Therapeutic agents can be delivered across the BBB following their linkage to either 
the Tf or a molecule able to specifically recognize the TfR.  
OX26, a mouse monoclonal antibody against the rat TfR1, has been explored as a 
drug delivery agent to the brain. It was used as an alternative to Tf itself in order to 
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prevent any eventual vector failure linked to a saturation of Tf receptors [18]. This 
antibody presents the advantage of binding to an extracellular domain for the TfR 
different from the Tf binding site and is therefore independent from Tf binding.  It has 
been thoroughly studied for the brain delivery of numerous drugs following 
intravenous administration [1,4-5]. For example, it was conjugated to the hydrophilic 
anti-cancer drug methotrexate by a hydrazone bond. Approximately six molecules of 
methotrexate were attached per antibody. After intravenous injection to rats, the 
conjugate was shown to be able to cross the blood-brain barrier via TfR-mediated 
transcytosis and to deliver the drug to the brain, as confirmed by 
immunohistochemical detection of the conjugate in the brain parenchyma [19]. 
In another example, the brain-derived neurotrophic factor (BDNF), a neuroprotective 
agent, cannot cross the BBB after intravenous administration and is unable to exert 
its neuroprotective effect in the first hours after regional brain ischemia, because the 
BBB is still intact at this stage. However, the intravenous administration of OX26 
conjugated to BDNF resulted in a 243% increase in motor performance of rats 
presenting stroke symptoms in comparison to the drug alone [20].  
OX26 has also been used to deliver many other drugs, such as neuropeptides 
(vasoactive intestinal peptide) [21], proteins (nerve growth factor) [22], to the rat brain 
after intravenous administration. As OX26 is specific to the rat TfR, another 
monoclonal antibody anti-mouse TfR, named 8D3, has been used as a TfR1-
targeting vector in the mouse [18]. This antibody, conjugDWHGWRUDGLRODEHOHG$ȕ1-40, 
has been used to visualize and quantify ȕ-amyloid plaques in a mouse model of 
$O]KHLPHUµVGLVHDVH [23]. A chimeric form of the 8D3 antibody was also conjugated to 
the glial-derived neurotrophic factor (GDNF), a neurotrophin with therapeutic 
potential on 3DUNLQVRQ¶V GLVHDVH. The GDNF-antibody fusion protein was able to 
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cross the BBB after intravenous injection and was found to be therapeutically active 
in three neurobehavior models of experimental ParkLQVRQ¶VGLVHDVHLQmice [24].  
 
Various approaches have been developed for the linkage of the drugs to Tf or anti-
TfR antibodies. Among them, the avidin/biotin technology appears to be particularly 
promising for the delivery of drugs to the brain. The non-covalent binding between 
avidin and biotin is extremely strong (Kd~ 10-15 M) and stable in the circulation, but is 
labile in the tissues [25], thus facilitating the release of the drug once it reaches the 
brain. The avidin/biotin strategy was for example used to link OX26 and the 
vasoactive intestinal peptide (VIP), and resulted in an increase of cerebral blood flow 
following intravenous administration of this complex to rats [21].  
This approach has also been successful in delivering high molecular weight-enzymes 
to the brain. For example, the intravenous administration of 116 kDa-ȕ-galactosidase 
linked to the 8D3 monoclonal antibody via streptavidin-biotin binding resulted in a 10-
fold increase in brain uptake of the enzyme, without loss of activity, in a mouse model 
[26]. In this study, brain delivery has been confirmed by brain capillary depletion 
method and brain histochemistry. 
 
 2.2.2. TfR-targeted quantum rods 
Quantum rods are semiconductor nanoparticles widely used as luminescent probes 
for various biological applications. In addition to their well-known optical properties, 
they can be functionalized and carry therapeutic molecules. For example, Tf-
conjugated quantum rods complexed to the anti-retroviral drug saquinavir were 
successfully transported across an in vitro BBB model through transferrin receptor-
mediated transcytosis [27,28]. 
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2.2.3. TfR-targeted liposomes and lipid nanocapsules 
TfR-targeted liposomes are self-assembling vesicular structures based on one or 
more lipid bilayers encapsulating an aqueous core and able to recognize the Tf 
receptor. They can encapsulate hydrophilic drugs in their aqueous core or entrap 
lipophilic drugs in the lipid bilayer membrane.  The use of conventional liposomes for 
brain drug delivery was initially limited by their size (which has to be smaller than 200 
nm in diameter to allow drug delivery across the BBB [29] and by their rapid 
clearance by the reticuloendothelial system [30]. However, the latter problem was 
overcome by incorporating polyethylene glycol (PEG)- derivatized lipids in the lipid 
bilayer of the liposomes or by coating them with PEG, resulting in the formation of 
sterically stabilized (also called  stealth) liposomes.  
Tf-bearing liposomes have been used for the cerebral delivery of the anti-cancer drug 
5-fluorouracil. The intravenous administration of this therapeutic system resulted in a 
17-fold increase in the brain uptake of the drug compared to that was observed with 
the free drug, as demonstrated by biodistribution studies with the radiolabelled drug 
[31]. 
Antibody-directed liposomes, or immunoliposomes, have also been shown to be 
promising vectors for the targeted delivery of drugs to the brain. OX26 antibody was 
conjugated to PEG-coated liposomes encapsulating the anti-cancer agent 
daunomycin, which has a very low permeability through blood brain barrier. Brain 
delivery of OX26-bearing liposomes was higher than that of the non-targeted stealth 
liposomes, conventional liposomes or free daunomycin, following intravenous 
administration of the formulations to rats, as demonstrated by pharmacokinetic 
analysis [32].  
Another lipid-based vector for brain targeting, called lipid nanocapsule, has recently 
been developed as a strategy to protect the entrapped drug from chemical and 
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enzymatic degradation. This nanovector is made of a hydrophilic surfactant, Solutol® 
HS15, surrounding an oily core [33]. The conjugation of OX26 antibody to the surface 
of the lipid nanocapsules doubled their concentration in the brain compared to non-
targeted formulations, 24h after intravenous administration to rats [34]. 
 
2.2.4. TfR-targeted nanoparticles 
Nanoparticles are polymeric colloidal spheres made of natural or artificial polymers, 
and ranging in size from 10 to 1000 nm. They can entrap drugs in their matrix, 
encapsulate them in their core or carry them on their surface. Like liposomes, they 
can be coated with PEG to prevent their clearance by the reticuloendothelial system. 
Nanoparticles made of poly (butyl cyanoacrylate) (PBCA) or poly (d,l-lactide-co-
glycolide acid) (PLGA) are among the most frequently used nanoparticle formulations 
for drug delivery to the brain [35-38]. For example, Tf-bearing PLGA nanoparticles 
entrapping the analgesic tramadol exhibited anti-nociceptive effects in rats for 24 h 
following their intravenous administration [38]. Similar results were obtained in rats 
following intravenous treatment with OX26-bearing PLGA nanoparticles entrapping 
endomorphins [37]. 
In another study, gold nanoparticles linked to the peptide CLPFFD had the capacity 
to dHVWUR\ WKH DJJUHJDWHV RI ȕ-amyloid, similar to the ones found in the brains of 
SDWLHQWVVXIIHULQJIURP$O]KHLPHU¶VGLVHDVHEXWZHUHXQDEOHWRFURVVWKH%%%7KHLU
conjugation to a peptide sequence recognizing the TfR allowed them to cross the 
BBB and to reach the brain of rats following intravenous administration, as 
demonstrated by quantification of gold in brain tissue [39].   
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2.2.5. TfR-targeted hybrid micelles 
Micelles are small spherical structures with a hydrophilic surface and a hydrophobic 
core region. They recently attracted a lot of interest for the delivery of drugs to the 
brain due to their small size and ease of preparation [40]. A polyphosphoester hybrid 
micelle, consisting of Tf-conjugated PEG-poly(İ-caprolactone)  and the amphiphilic 
EORFN FRSRO\PHU SRO\ İ-caprolactone)-block-poly(ethyl ethylene phosphate), was 
used to encapsulate the BBB-impermeable anti-cancer drug paclitaxel [41].  This Tf-
bearing formulation enhanced intravenous delivery of the drug to the brain by 1.8-fold 
when compared to the non-targeted micelles and resulted in an improved anti-glioma 
activity in mice bearing intracranial glioma [41,42]. In these studies, only Tf-bearing 
formulations entrapping paclitaxel led to significant therapeutic effects on orthotopic 
glioma, thus rejecting the hypothesis that the delivery of the anti-cancer drug to the 
tumors might have been facilitated by the leakiness of tumor vessels.  
 
It is also important to note that the therapeutic effect of a hydrophobic drug, which is 
often used as a measure for drug delivery efficiency, may be explained by binding of 
the drug carrier system to the brain endothelium or its uptake by endothelial cells, 
followed by diffusion of the drug further into the brain parenchyma. It does not 
necessarily mean that the drug carrier system crossed the BBB. The use of non-
targeted delivery systems as controls is therefore highly important to confirm the TfR-
mediated BBB crossing.   
 
2.3. Targeted gene delivery  
Numerous brain-related diseases could be candidates for treatment by gene therapy. 
Unfortunately, the inability of the nucleic acids to cross the BBB limits their 
therapeutic applications. In addition, a widespread expression of the exogenous gene 
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throughout the entire brain would be needed for the treatment of most cerebral 
disorders.  
Viral delivery systems have been widely used for gene delivery, as they facilitate 
highly efficient transfer and expression of exogenous genes, but they can be 
immunogenic, cytopathic or recombinogenic, thus limiting their repeated 
administrations [43]. On the other hand, non-viral delivery systems have been 
explored as promising alternatives for gene delivery. Various approaches have been 
used to formulate TfR-targeted non-viral gene medicines able to transport nucleic 
acids to the brain following intravenous administration (Figure 1). 
 
2.3.1. TfR-targeted liposomes 
Various formulations of TfR-targeted liposomes have been investigated for the 
delivery of nucleic acids across the BBB.  
PlasmLG'1$HQFRGLQJȕ-galactosidase has been delivered to the rat brain following 
its encapsulation in OX26-bearing stealth liposomes [44]. This delivery system 
crossed the BBB via transferrin receptor-mediated transcytosis and led to gene 
expression deep within brain parenchyma. Some levels of gene expression were also 
observed in the liver and the spleen [44]. 
This targeting strategy has also demonstrated efficacy in an experimental model of 
3DUNLQVRQ¶VGLVHDVH (PD). In order to remediate to the deficiency in striatal tyrosine 
hydroxylase (TH) characteristic of the disease, PD rat models were intravenously 
injected with TfR-targeted liposomes carrying a TH expression plasmid. This 
administration led to a normalization of striatal TH immunoreactivity. By contrast, rats 
treated with non-targeted liposomes did not show any improvement of their 
pathology, thus highlighting the importance of TfR for brain delivery [45]. 
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TfR-targeting can also be used for the brain delivery of RNA interference (RNAi) in 
brain cancer therapy. One of the therapeutic strategies used in this instance was to 
knock-down the human epidermal growth factor (EGFR) which has a pro-oncogenic 
function in tumor cell growth and is overexpressed on tumors. The plasmid used 
encoded a RNA antisense to a specific region of the human EGFR mRNA. The 
liposomes encapsulating the nucleic acid were conjugated to an antibody anti-TfR to 
cross the BBB and to an antibody anti-human insulin receptor to reach the tumor 
once inside the brain. Intravenous administration of the formulation every week in 
mice with U87 intra-cranial brain tumors resulted in a 100% increase in survival time 
of the animals [46]. 
Similar experiments were also done in mice, using the rat 8D3 monoclonal antibody 
against mouse TfR instead than OX26 that specifically recognizes rat TfR.  8D3-
FRQMXJDWHG 3(*\ODWHG OLSRVRPHV HQFDSVXODWLQJ SODVPLG '1$ HQFRGLQJ ȕ-
galactosidase were able to deliver their cargo to the brain of mice following 
intravenous administration. When the enzyme expression was driven by a brain 
specific promoter, such as the glial fibrillary acidic protein promoter, gene expression 
was only observed in the brain, especially in the astrocytes, but not in any peripheral 
organs [47].   
 
2.3.2. TfR-targeted conjugates/complexes 
Another strategy to deliver nucleic acid therapeutics to the brain is to attach them to 
TfR-targeting ligands with the use of the avidin-biotin technology. This approach 
allowed Suzuki and colleagues [48] to image endogenous gene expression in the 
brain with sequence-specific antisense radiopharmaceutics. In this study, the 
biotinylated peptide nucleic acids were antisense agents to the rat glial fibrillary acidic 
protein (GFAP) mRNA or the rat caveolin-Į (CAV) mRNA. They were chelated to a 
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radionuclide and bound to a conjugate of streptavidin and OX26.  The intravenous 
administration of TfR-targeted GFAP antisense to rats bearing brain glial tumors did 
not image brain cancer, due to the down-regulation of GFAP mRNA in cancer. 
However, TfR-targeted CAV antisense did lead to a selective imaging of brain cancer 
as a result of the administration of the delivery system, owing to the up-regulation of 
CAV mRNA in brain glial tumors [48].  
Using the same avidin-biotin approach, the intravenous administration of a TfR-
targeted siRNA led to 69-81% decrease in luciferase gene expression in brain cancer 
[49].  
 
Dendrimers have recently been shown to be promising candidates for brain delivery, 
owing to their unique polymer architecture and easily modified surface groups. They 
are synthetic polymeric macromolecules of nanometer size, composed of multiple 
branched monomers that emerge radially from the central core [50]. Due to their 
unusual structure, dendrimers are characterized by the following properties that 
differentiate them from other polymers and make them attractive for gene delivery: 
monodisperse size, modifiable surface functionality, multivalency, water solubility and 
available internal cavity eventually suitable for drug delivery [50]. 
So far, only one dendrimer, polyamidoamine (PAMAM), has been studied as a 
vehicle to cross the BBB via TfR targeting [51]. In this study, transferrin was 
conjugated to PAMAM through bifunctional PEG and complexed to a plasmid DNA 
encoding green fluorescent protein (GFP). After intravenous administration to mice, 
the Tf-bearing PAMAM-DNA complex was able to cross the BBB and led to the 
expression of GFP in several brain regions such as the hippocampus, substantia 
nigra, the 4th ventricle, the cortical layer and caudate putamen. This gene expression 
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was about 2-fold higher than that observed following the administration of PAMAM 
and PAMAM-PEG complexes [51].   
In other studies, a dendrigraft, poly-L-lysine, was developed as a delivery system for 
the co-administration of the anti-cancer drug doxorubicin and a therapeutic plasmid 
DNA encoding TNF-related apoptosis-inducing ligand (TRAIL) for brain tumor 
therapy. The combination of gene therapy and chemotherapy within one TfR-targeted 
delivery system was hypothesized to provide a synergistic therapeutic effect for the 
treatment of glioma. The peptide HAIYPRH (T7) was used as a TfR-targeting ligand. 
Doxorubicin was covalently conjugated to the dendrigraft via a pH-triggered 
hydrazine bond, while the DNA was complexed to the carrier. Following intravenous 
administration to mice bearing orthotopic glioma tumors, the TfR- targeted system 
was shortly detected in the brain and in the glioma (within 1h post-administration). 
The combination treatment then resulted in a synergistic growth inhibition of the 
tumors, with a survival time increased by about 20 days compared to controls [29].   
 
Most studies described above demonstrated that their TfR-targeted delivery systems 
were able to cross the BBB by TfR-mediated transcytosis by showing that non-
targeted delivery systems were not able to do so. The proof of such transport 
mechanism could also be obtained either by capillary depletion method or 
morphological investigation of brain tissue.  
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3. Transferrin receptor-mediated delivery of therapeutic agents to cancer cells 
Traditional chemotherapeutic drugs can successfully eradicate tumors, but often 
have their use limited due to their non-specific toxicity to normal cells. To overcome 
this major problem, many tumor-targeting strategies are currently under development 
[52]. Among them, TfR targeting has been the object of intense research in the field 
of cancer therapy, owing to the overexpression of this receptor on malignant cells 
that can be up to 100-fold higher than that observed in normal cells [6-9]. This 
overexpression of TfR on cancer cells is much higher than that observed on the BBB 
and therefore limits any delivery of chemotherapeutics to the brain instead to tumors. 
Furthermore, TfR-targeted delivery systems were shown to be highly useful for the 
systemic treatment of brain tumors, as they were able to transport therapeutic agents 
across the BBB and to increase their delivery to brain tumors following intravenous 
administration, as further described below [29,49]. 
  
3.1. Targeted drug delivery 
A wide range of delivery strategies, including the linkage of drugs to Tf, entrapment 
of the drugs in TfR-targeted liposomes, vesicles and nanoparticles, have been 
investigated for TfR-mediated delivery of drugs to tumors (Figure 1).   
 
3.1.1. Linkage of drugs to Tf 
Many anti-cancer drugs have been conjugated to either Tf or an antibody against 
TfR. One of them, doxorubicin, is an effective and widely used anti-cancer 
anthracyclin drug which exhibits severe adverse effects, such as cardiotoxicity, 
nephrotoxicity, myelosuppression due to non-specific drug distribution, and 
emergence of drug-resistant cancer cells. To overcome these limitations, doxorubicin 
was conjugated with Tf by glutaraldehyde cross-linking. This resulted in an increase 
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of the in vitro cytotoxicity of the conjugate, with an IC50 decrease of up to 57-fold 
compared to the free drug in L929 murine fibrosarcoma cells [53].  In vivo studies on 
nude mice bearing H-MESO-1 tumors demonstrated that the intravenously-
administered Tf-Doxorubicin conjugate significantly decrease the size of the tumors 
and consequently increased the life span of the animals by 69%, compared to 30 % 
following administration of doxorubicin solution [54].  
Conjugation of doxorubicin to Tf could also overcome the resistance of some cancer 
cells to doxorubicin solution, for example in KB human oral carcinoma cells and 
MCF-7 human breast cancer cells [55]. The resistance to free doxorubicin could be 
further overcome by conjugating Tf-doxorubicin conjugate with the antineoplastic 
drug gallium nitrate, which is a competitive inhibitor of the circulating holoTf. The Tf-
doxorubicin-gallium nitrate conjugate was able to decrease the IC50 by 100-fold in 
doxorubicin-resistant MCF-7 human breast cancer cells [56]. 
Tf has also been conjugated to cisplatin, an alkylating agent used for treating 
testicular, ovarian and bladder cancers. The resulting conjugate was able to avoid 
metastatic growth of breast carcinoma cells in the lungs during in vivo experiments 
on rats. In addition, a clinical trial for advanced breast cancer has shown a high 
response rate to the Tf-cisplatin conjugate in 4 out of 11 patients, including one 
complete response, with only minor side effects [57]. 
  
3.1.2. TfR-targeted liposomes and vesicles 
Encapsulating an anti-cancer drug in Tf-bearing liposomes or other lipid-based 
vesicles can lead to an increase in anti-proliferative efficacy and reduction of non-
specific adverse effects. The intravenous administration of Tf-bearing liposomes 
encapsulating doxorubicin in nude mice bearing HepG2 human hepatoma 
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subcutaneous tumors, resulted in an increase of drug concentration in tumors and a  
subsequent decrease of tumor growth compared to doxorubicin solution [58].   
Liposomes can also be conjugated to anti-TfR monoclonal antibodies instead of Tf. 
Such a strategy was used by Suzuki and colleagues [59], who reported the efficacy 
of doxorubicin-encapsulating liposomes conjugated to the anti-human TfR 
monoclonal antibody OKT9, on K562/ADM human leukemia cells resistant to free 
doxorubicin. In this in vitro study, TfR-targeted doxorubicin was taken up by the cells, 
thus resulting in an increased cytotoxic activity compared to the drug solution. 
Tf-bearing palmitoyl glycol chitosan-based vesicles were also tested for the delivery 
of doxorubicin to A431 human epidermoid carcinoma and the drug-resistant 
A2780AD human ovarian carcinoma cells [60]. Increased cellular uptake and 
cytotoxicity were observed for Tf-bearing formulations as compared to doxorubicin 
solution. In vivo, however, none of the vesicular formulations could significantly delay 
the growth of A431 tumors after a single administration and were less active than the 
drug solution.  
Tf-bearing vesicles were also found to be extremely useful to evaluate the 
therapeutic efficacy of promising anti-cancer drugs unable to reach the tumors at 
therapeutic concentrations. This was the case for example for tocotrienol, a member 
of the vitamin E family of compounds. We have demonstrated that the entrapment of 
tocotrienol within Tf-bearing vesicles led to tumor regression and increase of the 
animal survival following intravenous administration to mice bearing A431 tumors. 
[61]. In a follow-up study, we showed that intravenously administered Tf-bearing 
multilamellar vesicles entrapping tocotrienol led to complete tumor eradication for 
40% of B16-F10 murine melanoma and 20% of A431 tumors, as well as 
improvement of animal survival [62,63]. A similar strategy allowed us to demonstrate 
that treatment with the green tea extract epigallocatechin gallate encapsulated in Tf-
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bearing vesicles resulted in tumor suppression of 40% of A431 and B16-F10 tumors 
following intravenous administration of the targeted formulation [64].  
 
3.1.3. TfR-targeted polymers and nanoparticles 
Polymers and nanoparticles have become promising drug delivery systems for 
cancer therapy, due to their multifunctional structure that allows the simultaneous 
transport of various drugs to cancer cells, leading to synergistic therapeutic effects in 
vivo. Polymers used as single polymeric systems or as part of nanoparticles are also 
biodegradable and non-toxic. They can be of natural origin, such as the 
polysaccharide chitosan, or synthetic, such as poly (lactic acid) and poly (lactic-co-
glycolic acid) (PLGA). TfR-targeting nanoparticles could be formulated to allow 
various kinetics of drug release depending of the pathology to be treated. For 
example, a slowly releasing polymer could be more advantageous for cancer 
treatment whereas a faster release may be required for acute brain disorders [65].Tf-
bearing PLGA-based nanoparticles loading the mitotic inhibitor paclitaxel increased 
the delivery of their cargo to C6 rat glioma subcutaneous tumors compared to the 
non-targeted vehicles, after 24h of intravenous administration to rats [66]. In another 
study, 50% of treated S-180 tumor-bearing mice showed a complete tumor 
regression following the intravenous administration of Tf-bearing PEGylated 
poly(cyanoacrylate) nanoparticles entrapping paclitaxel. The life span of the animals 
was significantly increased, with 3 mice surviving over 60 days post-treatment with 
the TfR-targeting nanoparticles [67].  
 
3.2. Targeted gene delivery 
The possibility of using genes as medicines to treat patients suffering from cancer is 
still hampered by the lack of safe carrier systems able to specifically deliver the 
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therapeutic nucleic acids to the tumors after intravenous administration. There is 
therefore an urgent need to develop efficacious gene delivery systems that should be 
target-specific, non-toxic, non-inflammatory, biodegradable and non- immunogenic. 
Among all the delivery systems currently being developed, non-viral delivery systems 
appear most suited to fulfill these requirements. Moreover, they present the 
advantages of being easy to prepare, flexible regarding the size of nucleic acid to be 
carried and suitable for repeated administrations as they are much safer than viral 
vectors [68]. TfR-mediated gene delivery using these vectors is a promising strategy 
since it provides an opportunity to achieve specific gene delivery to tumors while 
increasing the transfection efficiency in cancer cells (Figure 1).  
 
3.2.1. TfR-targeted liposomes 
Cationic liposomes complexed with DNA have been used extensively for the delivery 
of nucleic acids to cancer cells in vitro and in vivo. The negatively charged DNA can 
be complexed to the positively charged liposomes by electrostatic interactions to 
form lipoplexes. The intravenous injection of a Tf-bearing lipoplex encoding for the 
tumor suppressor protein p53 resulted in high level of p53 gene expression in 
tumors, contrarily to what observed with non-targeted lipoplexes, in mice bearing 
subcutaneous DU145 human prostate tumors [69]. In combination with radiotherapy, 
the TfR-targeting lipoplex encoding p53 exhibited complete tumor regression without 
recurrence 6 months after treatment [69]. 
 
3.2.2.TfR-targeted cyclodextrins 
Cyclodextrins are a family of cyclic macromolecules consisting of 6-8 
glucopyranoside units linked together by glycosidic bonds to form a ring. They are 
characterized by their toroidal molecular structure with hydroxyl groups orientated 
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toward the outside. As a result, cyclodextrins are soluble in their aqueous 
environment while being able to host small hydrophobic drugs in their internal cavity 
to form inclusion complexes [70]. 
Cyclodextrins containing polycations have shown efficacy in transporting nucleic 
acids such as plasmid DNA and siRNA. A TfR-targeting PEGylated imidazole-
modified cyclodextrin was mixed with the siRNA targeting the EWS-FLI1 fusion 
protein known to be a transcription factor involved in tumorigenesis. Intravenous 
administration of this system in mice decreased gene expression of EWS-FLI1 in 
tumors and decreased the growth of tumors with short-term effect [71]. 
 
3.2.3. TfR-targeted micelles 
TfR-targeting micelles have demonstrated efficacy to deliver nucleic acids to tumors 
intravenously. Micelles made of a copolymer of poly (ethylene glycol)-poly(ethylene 
imine) biotin were associated to biotinylated Tf by avidin-biotin non-covalent binding 
[72]. This micellar formulation was demonstrated to enhance the tumor delivery of 
antisense oligonucleotides against the human multidrug resistance protein-1 (which 
plays a role in multidrug resistance) in MCF-7ADR human breast carcinoma as well 
as in KBV human oral epidermoid carcinoma [72].  
 
3.2.4. TfR-targeted polymers and dendrimers 
Many Tf-bearing polycationic polymers have been used to condense negatively 
charged DNA and to deliver it to cancer cells. Among them, polylysine and 
polyethylenimine (PEI) have been widely used for this purpose and both were found 
to be very efficient vectors for gene transfer to cancer cells.  In the K-562 human 
erythroleukemic cell line, most of the cell population was found to express the 
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transfected reporter genes following intravenous treatment with the Tf-bearing 
polylysine polyplex [73]. 
Similarly, Tf-bearing PEI was used to deliver a plasmid DNA encoding for tumor 
necrosis factor (TNF) Į D F\WRNLQH ZLWK SURPLVLQJ DQWL-cancer properties but also 
non-specific toxicity limiting its potential use. Systemic treatment of mice bearing 
either subcutaneous Neuro2a neuroblastoma, MethA fibrosarcoma or M-3-melanoma 
cells with this targeted formulation resulted in anti-tumor effects on the three tumor 
models, with complete regression of MethA tumors [74,75]. The treatment was well 
tolerated by the animals.  
 
In addition to their role as drug carriers, dendrimers have also been investigated as 
potential vehicles for nucleic acids. Generation 5- poly (amido amine) (PAMAM) 
dendrimer coated with PEG was targeted to TfR by conjugation with the peptide T7. 
It was able to co-deliver the drug doxorubicin together with a therapeutic plasmid 
encoding TRAIL [76]. A synergistic efficacy was observed between the 2 therapeutic 
agents following intravenous administration on mice bearing subcutaneous Bel-7402 
human hepatoma tumors. The TfR-targeting system inhibited 77% of tumor growth, 
which was much higher than that obtained with non-targeted dendriplex or the free 
drug, and this with a smaller dose [76].  
Recently, we have also demonstrated that an intravenously administered generation 
3-diaminobutyric polypropylenimine dendrimer (DAB) conjugated to Tf by cross-
linking DQG FRPSOH[HG WR SODVPLG '1$ HQFRGLQJ 71)Į OHG WR FRPSOHWH
disappearance of 90% of A431 human epidermoid carcinoma  tumors, compared to 
the 40% complete tumor regression observed with the non-targeted dendriplex [77]. 
In another study, we used this targeted dendrimer to assess the therapeutic potential 
of p73, a member of the p53 family of transcription factors. We demonstrated that the 
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intravenous administration of Tf-bearing, p73-encoding DAB dendriplex led to a 
sustained inhibition of tumor growth and complete tumor suppression for 10% of 
A431 and B16-F10 tumors in mice [78]. The treatments with both dendriplexes were 
well tolerated by the animals.  
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CONCLUSION 
A major challenge for the development of potential drugs with promising therapeutic 
effects resides in their inability to specifically reach the pathological site following 
intravenous administration, without generating secondary effects to healthy tissues.    
In the past few decades, the protein transferrin has been extensively explored as a 
targeting molecule for the transport of drug and gene delivery systems to the brain 
and cancer cells. A wide range of delivery approaches highlighted in this review are 
currently under investigation in laboratory settings and have already led to significant 
improvements in the systemic delivery of transferrin-bearing therapeutic systems to 
their site of action. Clinical trials exploring the efficacy of Tf-bearing therapeutics are 
already under way. These advances therefore demonstrate that the targeting of 
transferrin receptor has a huge potential for the development of more specific and 
safer gene and drug-based therapeutics.  
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FUTURE PERSPECTIVE  
Transferrin receptor targeting has shown promises for the delivery of nucleic acids 
and drugs across the blood-brain barrier and to tumors. It is a research area in full 
expansion, which is currently the object of intense patenting worldwide.  
In the future, it is likely that researchers will continue to develop novel TfR-targeted 
delivery systems or other techniques to further increase the specificity of the 
targeting to the pathological tissues. In addition, it will probably become important to 
focus on how to increase the transfection efficacy to optimize the therapeutic effect of 
potential gene medicines. One possibility would be to develop a strategy for 
facilitating the release of nucleic acids from the endosome to the cytoplasm of the 
cells.  
Although highly promising, most current research on TfR-based targeted delivery of 
drugs and nucleic acids is still at an early stage requiring more optimization. Some 
clinical trials are already under way. One of them, which has for objective to test the 
efficacy of a Tf-cisplatin conjugate for advanced breast cancer, has already shown 
highly positive results in a Phase I study  [57] and will hopefully pave the way for 
many more trials to come.  
More generally, targeting the delivery of a drug to its site of action can dramatically 
increase its therapeutic potential. Given the significant improvements already 
realized in the field of TfR targeting, it is likely that targeted delivery technologies will 
play a crucial role in the development of future therapeutics.  
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EXECUTIVE SUMMARY 
Introduction:  
x The use of promising novel therapeutics is limited by their inability to 
specifically reach the pathological site after intravenous administration, 
resulting in toxicity to healthy tissues.  
 
x Transferrin has been extensively studied as a targeting moiety for drug and 
gene delivery system, as its receptors are overexpressed on the blood-brain 
barrier and on cancer cells. 
 
Transferrin receptor-mediated delivery of therapeutic agents to the brain and to 
cancer cells: 
x A wide range of delivery systems targeting the transferrin receptor have been 
developed for the delivery of nucleic acids and drugs. 
 
x  Transferrin-bearing vehicles entrapping nucleic acids and drugs have been 
shown to specifically deliver their cargo to their required site of action and to 
improve their therapeutic effects.  
 
Conclusion: 
x Transferrin-bearing delivery systems are therefore highly promising for the 
delivery of therapeutics to the brain and tumors in vitro and in vivo, and should 
be further investigated. 
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REFERENCE ANNOTATIONS 
Publications of special note have been highlighted as: 
* of interest 
** of considerable interest 
 
** 52 Daniels TR, Bernabeu E, Rodriguez JA, et al. The transferrin receptor and the 
targeted delivery of therapeutic agents against cancer. Biochim. Biophys. Acta 1820, 
291-317 (2012). 
Very detailed description of the transferrin, its receptor and all the TfR-targeting 
delivery strategies attempted so far. 
 
** 74 Kircheis R, Ostermann E, Wolschek MF, et al. Tumor-targeted gene delivery of 
tumor necrosis factor-alpha induces tumor necrosis and tumor regression without 
systemic toxicity. Cancer Gene Ther. 9, 673-680 (2002).  
Demonstrates that the systemically administered Tf-bearing PEI encoding TNFĮ
resulted in anti-tumor effects on three tumor models, with complete regression of 
MethA tumors.  
 
** 77 Koppu S, Oh YJ, Edrada-Ebel R, et al. Tumor regression after systemic 
administration of  a novel tumor-targeted gene delivery system carrying a therapeutic 
plasmid DNA. J. Control. Release 143, 215-221 (2010). 
Demonstrates that an intravenously administered Tf-bearing DAB dendriplex 
HQFRGLQJ71)Į OHG WRFRPSOHWHGLVDSSHDUDQFHRIRI$KXPDQHSLGHUPRLG
carcinoma  tumors in mice. 
 38 
* 47 Shi NY, Zhang Y, Zhu CN, Boado RJ, Pardridge WM. Brain-specific expression 
of an exogenous gene after i.v. administration. Proc. Natl. Acad. Sci. USA 98, 12754-
12759 (2001). 
Demonstrates that 8D3-conjugated PEGylated liposomes encapsulating plasmid 
'1$HQFRGLQJȕ-galactosidase were able to deliver their cargo to the brain of mice 
following intravenous administration. When the enzyme expression was driven by a 
brain specific promoter, gene expression was only observed in the brain.   
 
* 57 Head JF, Wang F, Elliott RL. Antineoplastic drugs that interfere with iron 
metabolism in cancer cells. Adv. Enzyme Regul. 37, 147-159 (1997). 
Describes that a clinical trial for advanced breast cancer has shown a high response 
rate to the Tf-cisplatin conjugate in 4 out of 11 patients, including one complete 
response, with only minor side effects. 
 
* 62 Fu JY, Zhang W, Blatchford DR, Tetley L, McConnell G, Dufès C. Novel 
tocotrienol-entrapping vesicles can eradicate solid tumors after intravenous 
administration. J. Control Release 154, 20-26 (2011). 
Describes that intravenously administered Tf-bearing multilamellar vesicles 
entrapping tocotrienol led to complete tumor eradication for 40% of B16-F10 murine 
melanoma and 20% of A431 tumors, as well as improvement of animal survival. 
 
* 76 Han L, Huang R, Li J, Liu S, Huang S, Jiang C. Plasmid pORF-hTRAIL and 
doxorubicin co-delivery targeting to tumor using peptide-conjugated polyamidoamine 
dendrimer. Biomaterials 32, 1242-1252 (2011). 
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Demonstrates that a TfR-targeted PEGylated PAMAM dendrimer was able to co-
deliver the drug doxorubicin together with a therapeutic plasmid encoding TRAIL to 
tumors and to inhibit 77% of tumor growth.  
 
 
 
 
 
 
 
 40 
DEFINED KEY TERMS  
Blood-brain barrier 
The BBB is a complex interface separating the peripheral circulation from the central 
nervous system. It is formed by brain microvascular endothelial cells connected by 
tight junctions. The resulting continuous endothelial wall is further reinforced by 
pericytes, astrocytic endfeet and vascular nerve endings surrounding the endothelial 
cells. This protective structure therefore prevents the delivery of most intravenously 
administered drugs to the brain [27].  
 
Avidin/biotin technology 
Avidin is a glycoprotein obtained from egg white, known for its very high affinity for 
biotin, a vitamin that plays a role in numerous biological processes such as cell 
growth and the production of fatty acids. The avidin-biotin complex is the strongest 
known interaction between a ligand and a protein in nature, and has been shown to 
be resistant to extreme pH and temperature conditions [25].  
 
Stealth liposomes 
Stealth liposomes are grafted with a polymer (generally PEG), to prevent detection 
by the reticulo-endothelial system. This strategy therefore increases the circulating 
time of the delivery system compared to conventional liposomes [32,44].  
 
Dendrigraft 
A dendrigraft is a dendrimeric-shaped polymer formed by stepwise conjugation of 
tree-shaped branches on a central core.  
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'endriplex 
A dendriplex is a complex of nucleic acids with a dendrimer. 
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FIGURE  
 
 
 
 
Figure 1. Examples of formulation strategies used for the delivery of drugs and 
nucleic acids to the brain and tumor (³7I´WUDQVIHUULQ³7I5P$E´PRQRFORQDODQWibody 
anti-transferrin receptor. Formulation name in blue: delivery to the brain, in green: 
delivery to the tumor, in black: delivery to either brain or tumor). 
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